Abstract:Small animal fluorescence molecular imaging (FMI) can be a powerful tool for preclinical drug discovery and development studies. However, light absorption by tissue chromophores (e.g., hemoglobin, water, lipids, melanin) typically limits optical signal propagation through thicknesses larger than a few millimeters. Compared to other visible wavelengths, tissue absorption for red and near-infrared (near-IR) light absorption dramatically decreases and non-elastic scattering becomes the dominant light-tissue interaction mechanism. The relatively recent development of fluorescent agents that absorb and emit light in the near-IR range (600-1000 nm), has driven the development of imaging systems and light propagation models that can achieve whole body three-dimensional imaging in small animals. Despite great strides in this area, the ill-posed nature of diffuse fluorescence tomography remains a significant problem for the stability, contrast recovery and spatial resolution of image reconstruction techniques and the optimal approach to FMI in small animals has yet to be agreed on. The majority of research groups have invested in charge-coupled device (CCD)-based systems that provide abundant tissue-sampling but suboptimal sensitivity, while our group and a few others have pursued systems based on very high sensitivity detectors, that at this time allow dense tissue sampling to be achieved only at the cost of low imaging throughput. Here we demonstrate the methodology for applying single-photon detection technology in a fluorescence tomography system to localize a cancerous brain lesion in a mouse model. The fluorescence tomography (FT) system employed single photon counting using photomultiplier tubes (PMT) and information-rich time-domain light detection in a non-contact conformation. This provides a simultaneous collection of transmitted excitation and emission light, and includes automatic fluorescence excitation exposure control, laser referencing, and co-registration with a small animal computed tomography (microCT) system. A nude mouse model was used for imaging. The animal was inoculated orthotopically with a human glioma cell line (U251) in the left cerebral hemisphere and imaged 2 weeks later. The tumor was made to fluoresce by injecting a fluorescent tracer, IRDye 800CW-EGF (LI-COR Biosciences, Lincoln, NE) targeted to epidermal growth factor receptor, a cell membrane protein known to be overexpressed in the U251 tumor line and many other cancers. A second, untargeted fluorescent tracer, Alexa Fluor 647 (Life Technologies, Grand Island, NY) was also injected to account for non-receptor mediated effects on the uptake of the targeted tracers to provide a means of quantifying tracer binding and receptor availability/density. A CT-guided, time-domain algorithm was used to reconstruct the location of both fluorescent tracers (i.e., the location of the tumor) in the mouse brain and their ability to localize the tumor was verified by contrast-enhanced magnetic resonance imaging. Though demonstrated for fluorescence imaging in a glioma mouse model, the methodology presented in this video can be extended to different tumor models in various small animal models potentially up to the size of a rat.

Bioluminescence and Fluorescence Based 3-D Imaging of Tumor in a Spontaneous Pancreatic Tumor Model

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Use Of The Odd-Luciferase Transgene For The Non-Invasive Imaging Of Spontaneous Tumors In Mice

Real-time Bioluminescence and Tomographic Imaging of Gastric Cancer in a Novel Orthotopic Mouse Model.

In Vivo Fluorescence Reflectance Imaging with Subcutaneous Mouse Tumor Models.

Non-Invasive Direct Visualization of Luciferase-Luciferin Emitted Light Producing True Images from an Orthotopic Lung Cancer Xenograft Model in Nude Mice Using an Ultra-sensitive Low-light Camera and Optics

Molecular Imaging of Tumor Angiogenesis and Therapeutic Effects with Dual Bioluminescence

In Vivo Bioluminescence Tomography-Guided System for Pancreatic Cancer Radiotherapy Research

<i>In</i><i> vivo</i> bioluminescence imaging of granzyme B activity in tumor response to cancer immunotherapy

In Vivo Bioluminescence Tomography-Guided Radiation Research Platform for Pancreatic Cancer: an Initial Study Using Subcutaneous and Orthotopic Pancreatic Tumor Models.

Imaging of Red-Shifted Light From Bioluminescent Tumors Using Fluorescence by Unbound Excitation From Luminescence

Intravenous Administration-Oriented Pharmacokinetic Model for Dynamic Bioluminescence Imaging

In Vivo Quantitative Bioluminescence Tomography Using Heterogeneous and Homogeneous Mouse Models

Time Course of Bioluminescent Signal in Orthotopic and Heterotopic Brain Tumors in Nude Mice

Targeting the Insulin Growth Factor-1 Receptor with Fluorescent Antibodies Enables High Resolution Imaging of Human Pancreatic Cancer in Orthotopic Mouse Models

Compact Whole-Body Fluorescent Imaging of Nude Mice Bearing Egfp Expressing Tumor

Intravital Fluorescence Facilitates Measurement of Multiple Physiologic Functions and Gene Expression in Tumors of Live Animals

Targeted Bioluminescent Imaging of Pancreatic Ductal Adenocarcinoma Using Nanocarrier-Complexed EGFR-Binding Affibody–Gaussia Luciferase Fusion Protein

Optical Imaging: Bacteria, Viruses, and Mammalian Cells Encoding Light-Emitting Proteins Reveal the Locations of Primary Tumors and Metastases in Animals

Image-guided Simulation for Bioluminescence Tomographic Imaging.

Computed tomography-guided time-domain diffuse fluorescence tomography in small animals for localization of cancer biomarkers